

Pathological features of diabetic retinopathy in unilaterally nephrectomized Spontaneously Diabetic Torii fatty rats given 0.3% saltwater

Yoshiaki Tanaka¹, Rina Takagi¹, Machiko Shimmura-Tomita¹, Fuminari Yamaguchi², Yuko Katayama², Tomohisa Suzuki², Masami Shinohara³, Takeshi Ohta⁴, Tomohiko Sasase⁴, and Akihiro Kakehashi¹

¹Department of Ophthalmology, Jichi Medical University, Saitama Medical Center, Saitama, Japan ²Research Division Biology Laboratory, SCOHIA PHARMA, Inc., Kanagawa, Japan

³CLEA Japan, Inc., Tokyo, Japan

⁴Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan

(Presentation Number - Posterboard Number: 2714 - B0245)

BACKGROUND

- •We previously reported on the Spontaneously Diabetic Torii (SDT) rat, which is an animal model of spontaneous type 2 diabetes with severe diabetic ocular complications. 1-4
- •The SDT fatty rat, established by introducing the *fa* allele (obesity gene) of the Zucker fatty rat into the SDT rat genome, is a new model of obese type 2 diabetes.⁵⁻¹¹
- •We reported that the SDT fatty rats developed more severe diabetic retinopathy (DR) earlier than the SDT rats. 12,13
- •It was reported recently that unilateral nephrectomy (Nx) and salt supplementation in Spontaneously Diabetic Torii (SDT) fatty rats expedite kidney disorders.¹⁴


PURPOSE

To clarify the pathological features of DR in unilaterally nephrectomized SDT fatty rats given 0.3% saltwater

METHODS

Animals

- Nx+0.3% salt SDT fatty rats: n=6
 With unilateral Nx/0.3% saltwater (study group)
- SDT fatty rats: n=6
 Without Nx/water without salt (control group)
- SD rats: n=6




Measurements

- Body weight
- Blood samples: Glucose, hemoglobin (Hb) A1c, insulin, blood urea nitrogen (BUN), creatinine (CRE), glomerular filtration rate (GFR)
- Retinal thickness (hematoxylin and eosin [HE] staining):
 The retinal thicknesses were measured 500, 1,000, and 1,500 microns from the optic nerve disc.
- Retinal folds (HE staining):
- The numbers of retinal folds, defined as deformation from the outer nuclear layer to the photoreceptor layer, were measured within 1,500 microns of the optic nerve disc.
- Immunostaining for glial fibrillary acidic protein (GFAP) and vascular endothelial growth factor (VEGF):


Quantitative analyses of the immunopositive regions were performed within 1,000 microns of the optic nerve disc using the Hybrid Cell Count Module (Keyence, Tokyo, Japan).

RESULTS

Body weight, Blood samples




- There were no significant differences in body weight among the groups.
- •The GFR in the Nx+0.3% salt SDT fatty rats $(4.8\pm1.3 \text{ mL/min}/1.73 \text{ m}^2)$ was worse (P<0.05) than in the SDT fatty rats $(22.3\pm4.9 \text{ mL/min}/1.73 \text{ m}^2)$.
- •However, the HbA1c in the Nx+0.3% salt SDT fatty rats (9.2±1.6%) improved (*P*<0.05) compared with the SDT fatty rats (12.5±0.6%).



Data are expressed as the mean \pm standard deviation (n=6). *P<0.05, **P<0.01. (Steel-Dwass test)

Retinal thickness



Retinal thickness 500 µm from the disc
P=0.064
P=0.09
P=0.043
P=0.09
P=0.043
P=0.043
P=0.043
P=0.08
P=0.13
P=0.08
P=0.18
P=0.08
P=0.18


• The mean retinal thicknesses 500 microns from the optic nerve disc were:

Nx+0.3% salt SDT fatty rats 205.7±35.9 microns
SDT fatty rats 201.1±18.4 microns

>SD rats 155.6 ± 27.5 microns $155.6 \pm 27.$

- The retinas were thicker in the SDT fatty rats than in the SD rats.
- However, the retinal thicknesses did not differ significantly between the Nx+0.3% salt SDT fatty rats and the SDT fatty rats.

Retinal folds




 The numbers of retinal folds within 1,500 microns of the optic nerve disc were:

>Nx+0.3%salt SDT fatty rats 1.50 ± 0.84 >SDT fatty rats 1.16 ± 0.52 >SD rats 0.08 ± 0.20

(Nx+0.3% salt SDT fatty rats vs. SDT fatty rats, P=0.78; Nx+0.3% salt SDT fatty rats vs. SD rats, P=0.009**; SDT fatty rats vs. SD rats, P=0.009**) (Steel-Dwass test)

- Retinal folds developed infrequently in the SD rats.
- No significant differences in the retinal folds were seen between the Nx+0.3% salt SDT fatty rats and the SDT fatty rats.

Immunostaining for GFAP and VEGF



Area ratios of GFAP positivity

>Nx+0.3% salt SDT fatty rats $8.2\pm2.2\%$ >SDT fatty rats $7.2\pm2.4\%$ >SD rats $2.4\pm0.8\%$

(Nx+0.3% salt SDT fatty rats vs. SDT fatty rats, P=0.84; Nx+0.3% salt SDT fatty rats vs. SD rats, P=0.01*; SDT fatty rats vs. SD rats, P=0.03*) (Steel-Dwass test)

Area ratios of VEGF positivity

➤Nx+0.3% salt SDT fatty rats 6.3±2.3%

>SDT fatty rats $4.5\pm1.8\%$ >SD rats $3.7\pm1.7\%$

(Nx+0.3% salt SDT fatty rats vs. SDT fatty rats, P=0.32; Nx+0.3% salt SDT fatty rats vs. SD rats, P=0.13; SDT fatty rats vs. SD rats, P=0.80) (Steel-Dwass test)

 There were no significant differences in the quantitative analyses of the GFAP- and VEGF-positive regions in the retinas between the Nx+0.3% salt SDT fatty rats and SDT fatty rats.

CONCLUSIONS

- Severe DR developed in both the Nx+0.3% salt SDT fatty and SDT fatty rats compared with the SD rats.
- However, the progression of DR in the Nx+0.3% salt SDT fatty rats was not marked compared with the SDT fatty rats.
- The progression of DR may have been suppressed by the improvement in the blood glucose level despite development of kidney dysfunction due to unilateral Nx and salt supplementation.
- Further analysis and examination are needed.

REFERENCES

Toyoda F, Kakehashi A et al. The Open Diabetes J. 4, 108-113, 2011

Sasase T, Morinaga H et al. Diabetes Obes Metab. 11, 1084-1087, 2009

Sasase T, Ohta T et al. Diabetes Obes Metab. 8, 501-507, 2006

Toyoda F, Tanaka Y et al. J. Diabetes Res. 2016, Article ID 2345141, 2016

Shinohara M, Masuyama T, Kakehashi A et al. Int J Exp Diabetes Res. 1, 89-100, 2000

Ohta T, Matsui K et al. Exp. Anim. 56, 355-362, 2007

Sasase T, Ohta T et al. Exp. Anim. 57, 111-121, 2008

9. Ishii Y, Maki M et al. Exp. Anim. 59, 525-529, 2010

10. Yamaguchi T, Sasase T et al. J. Bone Miner. Metab. 30, 312-320, 2012

11. Kimura S, Sasase T et al. J. Bone Miner. Metab. 30, 312-320, 2012

12. Tanaka Y, Kobayashi M et al. ARVO, 2018

13. Motohashi Y, Kemmochi Y et al. Physiol Res. 67, 423-432, 2018

14. Briand F, Shinohara M et al. 2017 Kidney Week

Commercial Relationships; Yoshiaki Tanaka, Rina Takagi, Machiko Shimmura-Tomita, and Akihiro Kakehashi : Code N (No Commercial Relationship) Fuminari Yamaguchi, Yuko Katayama, and Tomohisa Suzuki : SCOHIA PHARMA, Inc. : Code E (Employment)

Masami Shinohara: CLEA Japan, Inc.: Code E (Employment), Takeshi Ohta and Tomohiko Sasase: Japan Tobacco Inc.: Code E (Employment)